
|Articles|October 1, 2002
Commitment to R&D strengthens Allergan product pipeline
Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
2
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
3
Proactive strategies and sustained delivery advance glaucoma care
4
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
5

















































.png)


